Most Read
Abstract
Objective: Emergence of multidrug resistance among Acinetobacter spp. complicates treatment of serious infections due to these organisms. Tigecycline is a member of a new class of antimicrobials, the glycylcyclines.
Methods: In this study, we evaluated the in vitro activity of tigecycline in 121 multidrug resistant (MDR) A. baumannii isolates by E-test® (AB Biodisk, Sweden).
Results: Among these isolates, 96 (79%) were susceptible to tigecycline, 19 (16%) showed intermediate susceptibility and 6 (5%) were resistant. MIC50 and MIC90 were 1.5 and 4 µg/ml, respectively. Seventy four per cent of carbapenem resistant isolates were found to be susceptible to tigecycline.
Conclusion: In conclusion, tigecycline may prove useful in treating infections due to MDR Acinetobacter species.